Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03861780 · ClinicalTrials.gov registry record · Phase 3
Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation
A Phase 3 study of Bacteria Microflora Reduction, sponsored by Professional Disposables International.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 1
- Study location
NCT03861780: Completed Phase 3 study of Bacteria Microflora Reduction, sponsored by Professional Disposables International.
NCT03861780 is a Phase 3 study of Bacteria Microflora Reduction that has completed, run by Professional Disposables International. The registered enrollment target is 152 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03861780, a Phase 3 study of Bacteria Microflora Reduction, has completed, sponsored by Professional Disposables International.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 1
- Study location
Study Summary
Comparative Study of Antimicrobial Effectiveness Evaluation of 26ml Project X, 5.1ml Project X and Prevantics Maxi Swabstick following ASTM E1173 - Standard Test Method for Evaluation of Preoperative, Precatheterization, or Preinjection Skin Preparations, ASTM International, West Conshohocken, Pennsylvania, 2015
Primary Outcome
Bacterial microflora (log10) will be measured via cup scrub method administration of the intervention
Conditions Studied
Interventions
- DRUG Project X 26ml
- DRUG Project X 5.1ml
- DRUG Prevantics Maxi Swabstick
Study Locations (1)
Montana
- Bioscience Laboratories Inc - Bozeman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2019-06-06 |
| Phase | Phase 3 |
What the finished NCT03861780 record still lists
NCT03861780 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Bacteria Microflora Reduction appearing as the primary indexed condition, and to 3 interventions - of which Project X 26ml is the first listed.
NCT03861780 reports a single indexed study location in Montana.
Frequently Asked Questions
What is clinical trial NCT03861780 about?
NCT03861780 is a clinical study titled "Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation". Comparative Study of Antimicrobial Effectiveness Evaluation of 26ml Project X, 5.1ml Project X and Prevantics Maxi Swabstick following ASTM E1173 - Standard Test Method for Evaluation of Preoperative, Precatheterization, or Preinjection Skin Preparations, ASTM International, West Conshohocken, Penns...
What is the current status of trial NCT03861780?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2019-04-02. Estimated completion is 2019-06-06.
What conditions does trial NCT03861780 study?
This clinical trial studies the following conditions: Bacteria Microflora Reduction.
What interventions are being tested in trial NCT03861780?
The interventions under investigation include: Project X 26ml (DRUG), Project X 5.1ml (DRUG), Prevantics Maxi Swabstick (DRUG).
Who is sponsoring clinical trial NCT03861780?
This trial is sponsored by Professional Disposables International, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03861780 being conducted?
This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03861780's enrollment target sits among peer trials
152 1513th of 2000 higher than 484 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI